You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN, Feb. 16, 2021 /PRNewswire/ -- The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2020" report has been added to ResearchAndMarkets.com's offering. The Global Gene Therapy Partnering Agreements 2010-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Comprehensive access to 530 actual gene therapy deals entered into by the world's biopharma companies, together with real world clause examples. The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.Global Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits: In-depth understanding of gene therapy deal trends since 2010 Access to headline, upfront, milestone and royalty data Analysis of the structure of gene therapy agreements with numerous real life case studies Full listing of gene therapy deals by company A-Z, deal value, phase of development, deal type, and therapy focus Identify leading gene therapy deals by value since 2010 Identify the most active gene therapy dealmakers since 2010 Detailed access to actual gene therapy contracts enter into by the leading fifty bigpharma Insight into the terms included in gene therapy agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Key Topics Covered: Executive SummaryChapter 1 IntroductionChapter 2 Trends in Gene therapy dealmaking2.1. Introduction2.2. Gene therapy partnering over the years2.3. Most active Gene therapy dealmakers2.4. Gene therapy partnering by deal type2.5. Gene therapy partnering by therapy area2.6. Deal terms for Gene therapy partnering2.6.1 Gene therapy partnering headline values2.6.2 Gene therapy deal upfront payments2.6.3 Gene therapy deal milestone payments2.6.4 Gene therapy royalty ratesChapter 3 Leading Gene therapy deals3.1. Introduction3.2. Top Gene therapy deals by valueChapter 4 Most active Gene therapy dealmakers4.1. Introduction4.2. Most active Gene therapy dealmakers4.3. Most active Gene therapy partnering company profilesChapter 5 Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 Gene therapy dealmaking by technology typeChapter 7 Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmakingAppendicesAppendix 1 Gene therapy deals by company A-ZAppendix 2 Gene therapy deals by stage of developmentDiscoveryPreclinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulationAppendix 3 Gene therapy deals by deal typeAsset purchaseBigpharma outlicensingCo-developmentCollaborative R&DCo-marketCo-promotionCRADACross-licensingDevelopmentDistributionEvaluationGrantJoint ventureLicensingManufacturingMarketingOptionResearchSpin outSub-licenseSupplyTechnology transferAppendix 4 Gene therapy deals by therapy areaCardiovascularCentral Nervous SystemGenetic disordersHematologyImmunologyInfectivesMetabolicMusculoskeletalObstetricsOncologyOphthalmicsOrphan diseasePediatricsRespiratoryAppendix 5 Deal type definitionsFor more information about this report visit https://www.researchandmarkets.com/r/y4sz4b Media Contact: Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com

Answer: Global Gene Therapy Partnering Deals, Terms and Agreements Report 2020: Undertake Due Diligence to Assess Suitability of Your Proposed Deal Terms for Partner Companies